ALLK Stock Overview
A clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Allakos Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.91 |
| 52 Week High | US$3.41 |
| 52 Week Low | US$0.54 |
| Beta | 1.02 |
| 11 Month Change | -32.32% |
| 3 Month Change | 26.82% |
| 1 Year Change | -47.27% |
| 33 Year Change | -98.88% |
| 5 Year Change | -99.06% |
| Change since IPO | -97.10% |
Recent News & Updates
Allakos Runs Up Into A Near-Term Catalyst
Nov 07We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully
Aug 27
Recent updates
Allakos Runs Up Into A Near-Term Catalyst
Nov 07We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully
Aug 27We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
May 05We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09Shareholder Returns
| ALLK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.1% | -6.5% | -1.0% |
| 1Y | -47.3% | 14.6% | 30.3% |
Return vs Industry: ALLK underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: ALLK underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ALLK volatility | |
|---|---|
| ALLK Average Weekly Movement | 22.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALLK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALLK's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 131 | Robert Alexander | www.allakos.com |
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc. Fundamentals Summary
| ALLK fundamental statistics | |
|---|---|
| Market cap | US$83.91m |
| Earnings (TTM) | -US$178.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ALLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALLK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$178.75m |
| Earnings | -US$178.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALLK perform over the long term?
See historical performance and comparison